Volume 25, Number 11—November 2019
Dispatch
Human-to-Human Transmission of Influenza A(H3N2) Virus with Reduced Susceptibility to Baloxavir, Japan, February 2019
Emi Takashita
, Masataka Ichikawa, Hiroko Morita, Rie Ogawa, Seiichiro Fujisaki, Masayuki Shirakura, Hideka Miura, Kazuya Nakamura, Noriko Kishida, Tomoko Kuwahara, Hiromi Sugawara, Aya Sato, Miki Akimoto, Keiko Mitamura, Takashi Abe, Masahiko Yamazaki, Shinji Watanabe, Hideki Hasegawa, and Takato Odagiri
, Masataka Ichikawa, Hiroko Morita, Rie Ogawa, Seiichiro Fujisaki, Masayuki Shirakura, Hideka Miura, Kazuya Nakamura, Noriko Kishida, Tomoko Kuwahara, Hiromi Sugawara, Aya Sato, Miki Akimoto, Keiko Mitamura, Takashi Abe, Masahiko Yamazaki, Shinji Watanabe, Hideki Hasegawa, and Takato Odagiri
Table 1
Influenza viruses with I38 substitutions in polymerase acidic protein, Japan, 2018–19*
| Influenza type or subtype | Total frequency | Age group, y |
||||
|---|---|---|---|---|---|---|
| 0–11 | 12–19 | 20–64 | >65 | Unknown | ||
| A(H1N1)pdm09 | 5/323 (1.5) | 4/230 (1.7) | 1/35 (2.9) | 0/41 | 0/14 | 0/3 |
| A(H3N2) | 32/337 (9.5) | 26/215 (12.1) | 5/45 (11.1) | 1/54 (1.9) | 0/16 | 0/7 |
| B | 0/36 | 0/21 | 0/7 | 0/6 | 0/1 | 0/1 |
*Values are no./total (%).
Page created: October 16, 2019
Page updated: October 16, 2019
Page reviewed: October 16, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.